# I-Mab

Type: Company (NBP)

Source: GetYourBrief — https://getyourbrief.com/entity/i-mab
Canonical HTML page: https://getyourbrief.com/entity/i-mab

## Recent coverage (2 stories, network-wide)

### NBP & CRMZ Micro-Cap Earnings: $(0.16) vs $(0.04) EPS
2026-08-22 07:00:25 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Two micro-caps reported late-August earnings: biotech I-Mab posted $(0.16) EPS while CreditRiskMonitor posted $(0.04) EPS on $5.17M revenue. Divergent risk profiles—1.47 beta vs 0.22 beta—highlight small-cap earnings dynamics.
Full story: https://getfinancebrief.com/story/imab-creditriskmonitor-microcap-earnings-comparison

### I-Mab Posts $(0.16) EPS; $9 PT Implies 371% Upside
2026-08-22 07:00:16 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Full story: https://getbiobrief.com/story/imab-nbp-q3-2026-earnings-biotech-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.